Dextech Medical AB (FRA:LQ0)

Market Cap	16.63M +16.9%
Revenue (ttm)	n/a
Net Income	-583.33K
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8640
Previous Close	0.8720
Day's Range	0.8640 - 0.8780
52-Week Range	0.5400 - 1.1200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on hormone, somatostatin, or the treatment of acromegaly, neuroendocrin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LQ0

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error